{"bill": {"#text": " \n", "form": {"current-chamber": {"#tail": " \n", "@display": "yes", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n", "congress": {"#tail": " ", "@display": "yes", "#text": "113th CONGRESS"}, "#tail": " \n", "legis-num": {"#tail": "\n", "#text": "H. R. 4771"}, "official-title": {"#tail": " \n", "#text": "To amend the Controlled Substances Act to more effectively regulate anabolic steroids.", "@display": "yes", "pagebreak": {"#tail": "\n    "}}, "session": {"#tail": " \n", "@display": "yes", "#text": "2d Session"}, "distribution-code": {"#tail": " \n", "@display": "yes", "#text": "IB"}, "action": [{"action-date": {"#tail": " \n", "@date": "20140529", "#text": "May 29, 2014"}, "#tail": " \n", "action-desc": {"#tail": " \n", "#text": "\n        ", "committee-name": [{"@deleted-display-style": "strikethrough", "#tail": ", and in addition to the Committee on the ", "@committee-id": "HIF00", "@added-display-style": "italic", "#text": "Committee on Energy and Commerce"}, {"#tail": ", for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned", "@committee-id": "HJU00", "#text": "Judiciary"}], "sponsor": {"#tail": " (for himself and ", "#text": "Mr. Pitts", "@name-id": "P000373"}, "cosponsor": {"#tail": ") introduced the following bill; which was referred to the ", "#text": "Mr. Pallone", "@name-id": "P000034"}}, "#text": " \n"}, {"action-date": {"#tail": "\n", "@date": "20140915", "#text": "September 15, 2014"}, "#tail": "\n", "action-desc": {"#tail": "\n", "#text": "Additional sponsors: ", "cosponsor": [{"#tail": ", ", "#text": "Mr. Chaffetz", "@name-id": "C001076"}, {"#tail": ", ", "#text": "Mr. Ben Ray Luj\u00e1n of New Mexico", "@name-id": "L000570"}, {"#tail": ", ", "#text": "Ms. Shea-Porter", "@name-id": "S001170"}, {"#tail": ", and ", "#text": "Mr. Amodei", "@name-id": "A000369"}, {"#tail": "\n      ", "#text": "Ms. Duckworth", "@name-id": "D000622"}]}, "#text": "\n"}, {"action-date": {"#tail": "\n", "@date": "20140915", "#text": "September 15, 2014"}, "#tail": "\n", "action-desc": {"#tail": "\n", "#text": "Reported from the Committee on ", "committee-name": {"@deleted-display-style": "strikethrough", "#tail": " with an amendment", "@committee-id": "HIF00", "@added-display-style": "italic", "#text": "Energy and Commerce"}}, "#text": "\n", "action-instruction": {"#tail": " \n", "#text": "Strike out all after the enacting clause and insert the part printed in italic"}}, {"action-date": {"#tail": "\n", "@date": "20140915", "#text": "September 15, 2014"}, "#tail": "\n", "action-desc": {"#tail": "\n", "#text": "Reported from the ", "committee-name": {"#tail": " with an amendment; committed to the Committee of the Whole House on the State of the Union and ordered to be printed", "@committee-id": "HJU00", "#text": "Committee on the Judiciary"}}, "#text": "\n", "action-instruction": [{"#tail": "\n", "#text": "Strike out all after the enacting clause and insert the part printed in boldface roman"}, {"#tail": "\n", "#text": "For text of introduced bill, see copy of bill as introduced on May 29, 2014"}]}, {"#tail": "\n", "#text": "\n", "@display": "yes", "action-desc": {"#tail": "\n", "#text": "\n        ", "@display": "yes", "pagebreak": {"#tail": "\n      "}}}], "associated-doc": {"#tail": " \n", "@display": "yes", "#text": "[Report No. 113\u2013587, Parts I and II]", "@role": "report"}, "calendar": {"#tail": "\n", "@display": "yes", "#text": "Union Calendar No. 434"}, "legis-type": {"#tail": " \n", "#text": "A BILL"}}, "@bill-stage": "Reported-in-House", "@bill-type": "olc", "endorsement": {"action-date": [{"#tail": "\n", "@date": "20140915", "#text": "September 15, 2014"}, {"#tail": "\n", "@date": "20140915", "#text": "September 15, 2014"}], "#tail": "\n", "@display": "yes", "action-desc": [{"#tail": "\n", "#text": "Reported from the Committee on ", "committee-name": {"@deleted-display-style": "strikethrough", "#tail": " with an amendment", "@committee-id": "HIF00", "@added-display-style": "italic", "#text": "Energy and Commerce"}}, {"#tail": "\n  ", "#text": "Reported from the ", "committee-name": {"#tail": " with an amendment; committed to the Committee of the Whole House on the State of the Union and ordered to be printed", "@committee-id": "HJU00", "#text": "Committee on the Judiciary"}}], "#text": "\n"}, "@dms-id": "H64262D40BC88475CB7B3772A22FF4AC9", "@public-private": "public", "legis-body": [{"@style": "OLC", "@committee-id": "HIF00", "@changed": "added", "#tail": " \n", "section": [{"@section-type": "section-one", "#tail": "\n", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Designer Anabolic Steroid Control Act of 2014", "@value": "Designer Anabolic Steroid Control Act of 2014", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "HB8B120A7C0FA40F4B0DE071D84E421D5"}, {"#tail": "\n", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n", "#text": "Amendments to the Controlled Substances Act"}, "subsection": [{"#tail": "\n", "text": {"#tail": "\n", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 102(41) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:102/p:41"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 802(41)", "@value": "usc/21/802/41"}, "@parsable-cite": "usc/21/802", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Definitions"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Controlled Substances Act/s:102/p:41/sp:A"}, "#text": "in "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "#text": "\n          ", "@id": "H303650BA518C481C8DD277BB774822B3", "subparagraph": [{"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by striking ", "@entity-type": "act", "#text": "clause (xlix)", "@value": "Controlled Substances Act/s:102/p:41/sp:A/cl:xlix"}, "#text": "in ", "quote": {"#tail": " at the end;", "#text": "and"}}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H9AB0A43179164A43AD7D1E7AC6F1CB51", "#text": "\n            "}, {"#tail": "\n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " as ", "@entity-type": "act", "#text": "clause (xlx)", "@value": "Controlled Substances Act/s:102/p:41/sp:A/cl:xlx"}, {"#tail": "; and", "@entity-type": "act", "#text": "clause (lxxv)", "@value": "Controlled Substances Act/s:102/p:41/sp:A/cl:lxxv", "@proposed": "true"}], "#text": "by redesignating "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "HEE50B467F3044B78A4AAB2681B016135", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the following:", "@entity-type": "act", "#text": "clause (xlix)", "@value": "Controlled Substances Act/s:102/p:41/sp:A/cl:xlix"}, "#text": "by inserting after "}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "; and"}, "#tail": "\n          ", "clause": [{"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "5\u03b1-Androstan-3,6,17-trione;"}, "enum": {"#tail": "\n                ", "#text": "(l)"}, "#text": "\n                ", "@id": "H20145617058F4BF49BD1A7411FE79E30"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "6-bromo-androstan-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(li)"}, "#text": "\n                ", "@id": "H6439D3337CFD4741B5121BE8E0C50748"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "6-bromo-androsta-1,4-diene-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lii)"}, "#text": "\n                ", "@id": "HA3EA4DF57B7A48309B43B5D213E0B03B"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-androsta-1,4-diene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(liii)"}, "#text": "\n                ", "@id": "H8007CFC696844591B04CAF60BD317D8E"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-androst-4-ene-3\u03b2,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(liv)"}, "#text": "\n                ", "@id": "H044449C78833439DB446E364BFC463A2"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-17\u03b2-hydroxy-androst-4-en-3-one;"}, "enum": {"#tail": "\n                ", "#text": "(lv)"}, "#text": "\n                ", "@id": "H3249219F8FE44DC4AB8F1DB24E607971"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-17\u03b2-hydroxy-androst-4-ene-3,11-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lvi)"}, "#text": "\n                ", "@id": "H11390C77C920440D86EEB1D8FCDC82F3"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-androsta-1,4-diene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(lvii)"}, "#text": "\n                ", "@id": "H1D44CE1A047B49DB91EA8AA0737D72DD"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "2\u03b1,17\u03b1-dimethyl-17\u03b2-hydroxy-5\u03b1-androstan-3-one;"}, "enum": {"#tail": "\n                ", "#text": "(lviii)"}, "#text": "\n                ", "@id": "H46041FB2D1BB48B0A5356365F44A2DB2"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "2\u03b1,17\u03b1-dimethyl-17\u03b2-hydroxy-5\u03b2-androstan-3-one;"}, "enum": {"#tail": "\n                ", "#text": "(lix)"}, "#text": "\n                ", "@id": "HCC4AFB4A624A4BECB4F1A78AA41DD460"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "2\u03b1,3\u03b1-epithio-17\u03b1-methyl-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lx)"}, "#text": "\n                ", "@id": "HF2DE1198C0504321960860A82CB79325"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "[3,2-c]-furazan-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxi)"}, "#text": "\n                ", "@id": "HCFC6CB42450044EDABC1015D6A4C41C5"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "3\u03b2-hydroxy-estra-4,9,11-trien-17-one;"}, "enum": {"#tail": "\n                ", "#text": "(lxii)"}, "#text": "\n                ", "@id": "H6FC6D3B3037B4D7F898B32E1D574B9C8"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "17\u03b1-methyl-androst-2-ene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(lxiii)"}, "#text": "\n                ", "@id": "H5F697C776C414D69B30C421B355148FF"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "17\u03b1-methyl-androsta-1,4-diene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(lxiv)"}, "#text": "\n                ", "@id": "H6CF859162C924256B9D180B7AD55353E"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "Estra-4,9,11-triene-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lxv)"}, "#text": "\n                ", "@id": "HD8B1BAC98F084DE79F1AF3D322ABAA06"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one;"}, "enum": {"#tail": "\n                ", "#text": "(lxvi)"}, "#text": "\n                ", "@id": "H58B96893C85D48EE85703A3C0404A136"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "6\u03b1-Methyl-androst-4-ene-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lxvii)"}, "#text": "\n                ", "@id": "H662144FE5B474D4F9D666105AD86CE30"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "17\u03b1-Methyl-androstan-3-hydroxyimine-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxviii)"}, "#text": "\n                ", "@id": "H1C270B01F2434896AEB96D70E9DE2C75"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "17\u03b1-Methyl-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxix)"}, "#text": "\n                ", "@id": "H5E7748D4943E45D89D4848B1E5C20536"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "17\u03b2-Hydroxy-androstano[2,3-d]isoxazole;"}, "enum": {"#tail": "\n                ", "#text": "(lxx)"}, "#text": "\n                ", "@id": "HB2B43A41B3124052A84ADA3372D794DC"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "17\u03b2-Hydroxy-androstano[3,2-c]isoxazole;"}, "enum": {"#tail": "\n                ", "#text": "(lxxi)"}, "#text": "\n                ", "@id": "H5721A09526934FD7A40BB3B1E2C5BCF6"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxxii)"}, "#text": "\n                ", "@id": "H42242DBC13B5408EB795EA30CF060263"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n              ", "#text": "[3,2-c]pyrazole-androst-4-en-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxxiii)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "H4B235E54A9C74704A84FD4CAC4922EF0", "@commented": "no"}, {"@indent": "paragraph", "#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "[3,2-c]pyrazole-5\u03b1-androstan-17\u03b2-ol; and"}, "enum": {"#tail": "\n                ", "#text": "(lxxiv)"}, "#text": "\n                ", "@id": "H2F86FE9F8444451B980FD98A3F24C46A"}], "@display-inline": "no-display-inline", "#text": "\n", "@id": "HD051B9C5B7344CB4B017588F7659D47C"}, "#text": "\n            ", "@id": "HAEB4C71A9F8F494F9493950B9739F742"}]}, {"#tail": "\n      ", "text": {"#tail": "\n", "#text": "by adding at the end the following:"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "@id": "H8B94346A26594536BBC0ACCEC73FDBEF", "@display-inline": "no-display-inline", "#text": "\n", "subparagraph": {"@indent": "paragraph", "#tail": "\n            ", "clause": [{"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", a drug or hormonal substance (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that is not listed in ", "@entity-type": "act", "#text": "clause (ii)", "@value": "Controlled Substances Act/s:102/p:41/sp:C/cl:ii", "@proposed": "true"}, {"#tail": " and is derived from, or has a chemical structure substantially similar to, 1 or more anabolic steroids listed in ", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Controlled Substances Act/s:102/p:41/sp:A"}, {"#tail": " shall be considered to be an anabolic steroid for purposes of this Act if\u2014", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Controlled Substances Act/s:102/p:41/sp:A"}], "#text": "Subject to "}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "subclause": [{"@indent": "subparagraph", "#tail": "\n", "text": {"#tail": "\n", "#text": "the drug or substance has been created or manufactured with the intent of producing a drug or other substance that either\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "item": [{"@indent": "clause", "#tail": "\n", "text": {"#tail": "\n                  ", "#text": "promotes muscle growth; or"}, "enum": {"#tail": "\n                    ", "#text": "(aa)"}, "#text": "\n                    ", "@id": "H3AACCF12E7C745F18AD10D46B1ECF4FE"}, {"@indent": "clause", "#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "otherwise causes a pharmacological effect similar to that of testosterone; or"}, "enum": {"#tail": "\n                    ", "#text": "(bb)"}, "#text": "\n                    ", "@id": "HEC9D1D55DF3847FABC2CF0E3867F0E03"}], "#text": "\n                  ", "@id": "HBA22839FB69D4E1696444121E64CE88A"}, {"@indent": "subparagraph", "#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "the drug or substance has been, or is intended to be, marketed or otherwise promoted in any manner suggesting that consuming it will promote muscle growth or any other pharmacological effect similar to that of testosterone."}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "#text": "\n                  ", "@id": "HF81243E4A9914020935A3EADB17D092B"}], "@display-inline": "yes-display-inline", "#text": "\n                ", "@id": "HAB207834502F41648003584BC9C2008D", "@commented": "no"}, {"@indent": "paragraph", "#tail": "\n", "text": {"#tail": "\n", "#text": "A substance shall not be considered to be a drug or hormonal substance for purposes of this subparagraph if it\u2014"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "subclause": [{"@indent": "subparagraph", "#tail": "\n", "text": {"#tail": "\n", "#text": "is\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "item": [{"@indent": "clause", "#tail": "\n", "text": {"#tail": "\n                  ", "#text": "an herb or other botanical;"}, "enum": {"#tail": "\n                    ", "#text": "(aa)"}, "#text": "\n                    ", "@id": "H2EF2FC160B9F40989D87744251E0F21D"}, {"@indent": "clause", "#tail": "\n", "text": {"#tail": "\n                  ", "#text": "a concentrate, metabolite, or extract of, or a constituent isolated directly from, an herb or other botanical; or"}, "enum": {"#tail": "\n                    ", "#text": "(bb)"}, "#text": "\n                    ", "@id": "H2BA4A305A745475DAC38ED1877A5F89F"}, {"@indent": "clause", "#tail": "\n                ", "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "item (aa)", "@value": "Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:aa", "@proposed": "true"}, {"#tail": ";", "@entity-type": "act", "#text": "(bb)", "@value": "Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:bb", "@proposed": "true"}], "#text": "a combination of 2 or more substances described in "}, "enum": {"#tail": "\n                    ", "#text": "(cc)"}, "#text": "\n                    ", "@id": "HC6ED9EE91D034BE1BF4DF648EE55831F"}], "#text": "\n                  ", "@id": "H6C639530015C456993DFA3E959F1F792"}, {"@indent": "subparagraph", "#tail": "\n", "text": {"#tail": "\n                ", "#text": "is a dietary ingredient for purposes of the ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "; and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}, "@entity-type": "law-citation", "#text": "\n                      ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "uscode", "#text": "21 U.S.C. 301 et seq.", "@value": "usc/21/301/etseq"}, "@parsable-cite": "usc/21/301", "#text": "\n                      ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "#text": "\n                  ", "@id": "HCC10942380944F439A699CABB42016BB"}, {"@indent": "subparagraph", "#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "is not anabolic or androgenic.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(III)"}, "#text": "\n                  ", "@id": "H17EB67DA1B4A4E4BA5080BF3474C63AD"}], "#text": "\n                ", "@id": "H2BB4D63C842F43068E18D410B4E4D933"}, {"@indent": "paragraph", "#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", any person claiming the benefit of an exemption or exception under ", "@entity-type": "act", "#text": "section 515(a)", "@value": "Controlled Substances Act/s:515/ss:a"}, {"#tail": " shall bear the burden of going forward with the evidence with respect to such exemption or exception.", "@entity-type": "act", "#text": "clause (ii)", "@value": "Controlled Substances Act/s:102/p:41/sp:C/cl:ii", "@proposed": "true"}], "#text": "In accordance with "}, "enum": {"#tail": "\n                ", "#text": "(iii)"}, "#text": "\n                ", "@id": "HCA3202286FDC41C2A50FF9064621E9D2"}], "enum": {"#tail": "\n", "#text": "(C)"}, "#text": "\n              ", "@id": "H077BD6BC69BC492B8F084E6B26636F62"}}, "#text": "\n          ", "@id": "H8DFE92665CE641259F2BAEA838943EC8"}], "#text": "\n        ", "@id": "HC4170E83FFED4C348DEAADBAD2479AE0"}, {"#tail": "\n", "text": {"#tail": "\n", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 201 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:201"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 811", "@value": "usc/21/811"}, "@parsable-cite": "usc/21/811", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Classification authority"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "subsection": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(i)"}, "header": {"#tail": "\n", "#text": "Temporary and permanent scheduling of recently emerged anabolic steroids"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may issue a temporary order adding a drug or other substance to the definition of anabolic steroids if the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " finds that\u2014", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "#text": "\n              ", "@id": "H9468C38D96EC495184C76BC23A6B410C", "subparagraph": [{"#tail": "\n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " but is not listed in that section or by regulation of the ", "@entity-type": "act", "#text": "section 102(41)", "@value": "Controlled Substances Act/s:102/p:41"}, {"#tail": " as being an anabolic steroid; and", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "the drug or other substance satisfies the criteria for being considered an anabolic steroid under "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H15C6FB20F9A64090A695F0FDD109E936", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "adding such drug or other substance to the definition of anabolic steroids will assist in preventing abuse or misuse of the drug or other substance.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H6761A8ABB3674FE9BB77B3AE91EA0AD1", "#text": "\n                "}]}, {"#tail": "\n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall not take effect until 30 days after the date of the publication by the ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:201/ss:i/p:1", "@proposed": "true"}, {"#tail": " of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued. The order shall expire not later than 24 months after the date it becomes effective, except that the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " may, during the pendency of proceedings under ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": ", extend the temporary scheduling order for up to 6 months.", "@entity-type": "act", "#text": "paragraph (6)", "@value": "Controlled Substances Act/s:201/ss:i/p:6", "@proposed": "true"}], "#text": "An order issued under "}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "@id": "H149F2DF3AB404EBAA9A51D2AE8C4A061", "#text": "\n              "}, {"#tail": "\n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall transmit notice of an order proposed to be issued under ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " to the ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:201/ss:i/p:1", "@proposed": "true"}, {"#tail": ". In issuing an order under ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, {"#tail": ", the ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:201/ss:i/p:1", "@proposed": "true"}, {"#tail": " shall take into consideration any comments submitted by the Secretary in response to a notice transmitted pursuant to this paragraph.", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "@id": "HD1124F4D1AA743DB933742DEE21E5000", "#text": "\n              "}, {"#tail": "\n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall be vacated upon the issuance of a permanent scheduling order under ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:201/ss:i/p:1", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (6)", "@value": "Controlled Substances Act/s:201/ss:i/p:6", "@proposed": "true"}], "#text": "A temporary scheduling order issued under "}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "@id": "H4019B4D31A9844B2A09C5D16462E82D4", "#text": "\n              "}, {"#tail": "\n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " is not subject to judicial review.", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:201/ss:i/p:1", "@proposed": "true"}, "#text": "An order issued under "}, "enum": {"#tail": "\n              ", "#text": "(5)"}, "@id": "HF7847FE8E58747A8B726E1831E8D1B74", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, by rule, issue a permanent order adding a drug or other substance to the definition of anabolic steroids if such drug or other substance satisfies the criteria for being considered an anabolic steroid under ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": ". Such rulemaking may be commenced simultaneously with the issuance of the temporary order issued under ", "@entity-type": "act", "#text": "section 102(41)", "@value": "Controlled Substances Act/s:102/p:41"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:201/ss:i/p:1", "@proposed": "true"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(6)"}, "@id": "HED09590B30334F289B7D69ABDFE1E806", "#text": "\n              "}], "#text": "\n            ", "@id": "H58350DF488944E62BABADF68BD8A2F01"}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "H210BF3F319C5443AB27500AB4FF00A3F"}, "#text": "\n        ", "@id": "HBBAB2857C63B448596AFA1441FE976EA"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n", "#text": "Labeling requirements"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " is amended by inserting after ", "@entity-type": "act", "#text": "Controlled Substances Act", "@value": "Controlled Substances Act"}, "#text": "The ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 305", "@value": "Controlled Substances Act/s:305"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 825", "@value": "usc/21/825"}, "@parsable-cite": "usc/21/825", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "In general"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "section": {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "305A."}, "header": {"#tail": "\n", "#text": "Offenses involving false labeling of anabolic steroids"}, "subsection": [{"#tail": "\n", "enum": {"#tail": "\n                ", "#text": "(a)"}, "header": {"#tail": "\n", "#text": "Unlawful acts"}, "paragraph": [{"continuation-text": {"#tail": "\n                ", "@continuation-text-level": "paragraph", "#text": "any anabolic steroid, or any product containing an anabolic steroid, that does not bear a label clearly identifying any anabolic steroid contained in such steroid or product by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC)."}, "#tail": "\n", "text": {"#tail": "\n", "#text": "It shall be unlawful\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(1)"}, "#text": "\n                  ", "@id": "HE407646D58B04451A7C03EC6779B1F4E", "subparagraph": [{"#tail": "\n", "text": {"#tail": "\n                  ", "#text": "to import into the United States or to export from the United States;"}, "enum": {"#tail": "\n                    ", "#text": "(A)"}, "@id": "H774AE438212E460E9DA65A1A9DCAAD14", "#text": "\n                    "}, {"#tail": "\n", "text": {"#tail": "\n                  ", "#text": "to manufacture, distribute, dispense, sell, or offer to sell; or"}, "enum": {"#tail": "\n                    ", "#text": "(B)"}, "@id": "HE8A3669A1438431091D9C131DFC8389E", "#text": "\n                    "}, {"#tail": "\n                  ", "text": {"#tail": "\n                  ", "#text": "to possess with intent to manufacture, distribute, dispense, sell, or offer to sell;"}, "enum": {"#tail": "\n                    ", "#text": "(C)"}, "@id": "HBA2EC44F328042F886362EE689140087", "#text": "\n                    "}]}, {"#tail": "\n              ", "subparagraph": [{"#tail": "\n", "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this subsection if such product is labeled in the manner required under the ", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "Controlled Substances Act/s:305A/ss:a/p:2/sp:B", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}], "#text": "A product described in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(A)"}, "@display-inline": "yes-display-inline", "#text": "\n                    ", "@id": "H7F0D377D9A6D4BCFA748CB02E5078408"}, {"@indent": "up1", "#tail": "\n                ", "text": {"#tail": "\n", "#text": "A product is described in this subparagraph if the product\u2014"}, "enum": {"#tail": "\n                    ", "#text": "(B)"}, "clause": [{"#tail": "\n", "text": {"#tail": "\n                    ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, {"#tail": "; or", "@entity-type": "act", "#text": "(j) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}], "#text": "is the subject of an approved application as described in "}, "enum": {"#tail": "\n                      ", "#text": "(i)"}, "@id": "H74299C5F73E940C19BB2A7C68A6D5929", "#text": "\n                      "}, {"#tail": "\n                  ", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " of such Act relating to new drugs because\u2014", "@entity-type": "act", "#text": "section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, "#text": "is exempt from the provisions of "}, "enum": {"#tail": "\n                      ", "#text": "(ii)"}, "subclause": [{"#tail": "\n", "text": {"#tail": "\n                      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " of such Act; and", "@entity-type": "act", "#text": "section 505(i)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:i"}, "#text": "it is intended solely for investigational use as described in "}, "enum": {"#tail": "\n                        ", "#text": "(I)"}, "@id": "H65CB067BBC2C4CBAB83A8426DCF85C86", "#text": "\n                        "}, {"#tail": "\n                    ", "text": {"#tail": "\n                      ", "#text": "such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application."}, "enum": {"#tail": "\n                        ", "#text": "(II)"}, "@id": "H0D6026AA099E48E6837D78923C198B0D", "#text": "\n                        "}], "#text": "\n                      ", "@id": "H58F1F62223CF49CA9D16F6291EAC60B1"}], "#text": "\n                    ", "@id": "H67AD588A5CC94FE4A82CB21FA3A8FB86"}], "enum": {"#tail": "\n", "#text": "(2)"}, "@id": "HEB08818B11CD4AF5BACD61A51ACFD911", "#text": "\n                  "}], "#text": "\n                ", "@id": "HAC93E8F5A63948DE8ECA886B14BA9B5E"}, {"#tail": "\n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " knowing, intending, or having reasonable cause to believe, that the substance or product is an anabolic steroid, or contains an anabolic steroid, shall be sentenced to a term of imprisonment of not more than 10 years, a fine not to exceed the greater of that authorized in accordance with the provisions of ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Controlled Substances Act/s:305A/ss:a", "@proposed": "true"}, {"#tail": ", or $500,000 if the defendant is an individual or $2,500,000 if the defendant is other than an individual, or both.", "@entity-type": "uscode", "#text": "title 18, United States Code", "@value": "usc/18"}], "#text": "Any person who violates "}, "enum": {"#tail": "\n                ", "#text": "(b)"}, "header": {"#tail": "\n                ", "#text": "Criminal penalties"}, "#text": "\n                ", "@id": "H9CDE5447F2C9457CACD8FAF98ED3626B"}, {"#tail": "\n", "enum": {"#tail": "\n                ", "#text": "(c)"}, "header": {"#tail": "\n", "#text": "Civil penalties"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall be subject to a civil penalty as follows:", "@entity-type": "act", "#text": "subsection (a)", "@value": "Controlled Substances Act/s:305A/ss:a", "@proposed": "true"}, "#text": "Any person who violates "}, "enum": {"#tail": "\n                  ", "#text": "(1)"}, "#text": "\n                  ", "@id": "HFD46C43C608B46759B35EBE5115A4AE3", "subparagraph": [{"#tail": "\n", "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, or distribution, and each anabolic steroid or product imported, exported, manufactured, or distributed.", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "Controlled Substances Act/s:305A/ss:c/p:1/sp:B", "@proposed": "true"}, "#text": "In the case of an importer, exporter, manufacturer, or distributor (other than as provided in "}, "enum": {"#tail": "\n                    ", "#text": "(A)"}, "@id": "HF39ECE2582334D97AF6C64DEA44ECC29", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " shall be considered additional violations.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "In the case of a sale or offer to sell at retail, up to $25,000 per violation. For purposes of this subparagraph, each sale and each product offered for sale shall be considered a separate violation. Continued offers to sell by a person 10 or more days after written notice (including through electronic message) to the person by the "}, "enum": {"#tail": "\n                    ", "#text": "(B)"}, "@id": "H5138A7B9B65F4B4C868020967F330DD5", "#text": "\n                    "}]}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "term": {"#tail": " means a discrete article, either in bulk or in finished form prepared for sale. A number of articles, if similarly packaged and bearing identical labels, shall be considered as one product, but each package size, form, or differently labeled article shall be considered a separate product.", "#text": "product"}, "#text": "In this subsection, the term "}, "enum": {"#tail": "\n                  ", "#text": "(2)"}, "@id": "HB69585AA2DD0473EAD88FE44BF0E468D", "#text": "\n                  "}], "#text": "\n                ", "@id": "HA059AEFC2C5647AF96B87F1DEA54D89A"}, {"#tail": "\n            ", "enum": {"#tail": "\n                ", "#text": "(d)"}, "header": {"#tail": "\n", "#text": "Identification and publication of list of products containing anabolic steroids"}, "paragraph": [{"#tail": "\n", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, in his discretion, collect data and analyze products to determine whether they contain anabolic steroids and are properly labeled in accordance with this section. The ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " may publish in the Federal Register or on the website of the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " a list of products that he has determined, based on substantial evidence, contain an anabolic steroid and are not labeled in accordance with this section.", "@entity-type": "federal-body", "#text": "Drug Enforcement Administration", "@entity-id": "1524"}], "#text": "The "}, "enum": {"#tail": "\n                  ", "#text": "(1)"}, "@id": "H89D48C139BC74F968E1D43B6067071A4", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall not constitute evidence that the product does not contain an anabolic steroid.", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:305A/ss:d/p:1", "@proposed": "true"}, "#text": "The absence of a product from the list referred to in "}, "enum": {"#tail": "\n                  ", "#text": "(2)"}, "@id": "H9E91396AEA1F4A478B75A1D55611C9A8", "#text": "\n                  "}], "#text": "\n                ", "@id": "H514C2C9ADBEC4D09A1B69571A0715F5A"}], "#text": "\n              ", "@id": "HFF54F889ACF44A7D88BEA5BD17240E68"}, "@display-inline": "no-display-inline", "#text": "\n", "@id": "H4D5E90C98EC24517BF57254B02ED580F"}, "#text": "\n          ", "@id": "HB53DF7718A82494EB0E17B2A583C4DB2"}, {"#tail": "\n      ", "text": {"#tail": "\n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " is amended by inserting after the item relating to ", "@entity-type": "act", "#text": "Comprehensive Drug Abuse Prevention and Control Act of 1970", "@value": "Comprehensive Drug Abuse Prevention and Control Act of 1970"}, {"#tail": " the following:", "@entity-type": "act", "#text": "section 305", "@value": "Comprehensive Drug Abuse Prevention and Control Act of 1970/s:305"}], "#text": "The table of contents for the "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Table of contents"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "@display-inline": "no-display-inline", "toc": {"#tail": "\n            ", "#text": "\n", "toc-entry": {"#tail": "\n            ", "@level": "section", "#text": "Sec. 305A. Offenses involving false labeling of anabolic steroids.", "@bold": "off"}}, "#text": "\n", "@id": "HF969878EDF7F4EDF89FCB9C4C8655DC1"}, "#text": "\n          ", "@id": "H0598F3EB55DB40138E41C6922565B319"}], "#text": "\n        ", "@id": "H53D60F480A7341A2972F13DA36A3EF99"}], "#text": "\n      ", "@id": "H189FECF638EB445BB34865FDE8B09B67"}], "@display-enacting-clause": "yes-display-enacting-clause", "@reported-display-style": "italic", "#text": "\n", "@id": "H4D76B38E58454029A775CE8A90373DAF"}, {"@style": "OLC", "@committee-id": "HJU00", "@changed": "added", "#tail": "\n", "section": [{"@section-type": "section-one", "#tail": " \n", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Designer Anabolic Steroid Control Act of 2014", "@value": "Designer Anabolic Steroid Control Act of 2014", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "HDA55F5C4DBA443268D8DC9436C2CE230"}, {"#tail": " \n", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": " \n", "#text": "Amendments to the Controlled Substances Act"}, "subsection": [{"#tail": " \n", "text": {"#tail": " \n", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 102(41) of the Controlled Substances Act", "@value": "Controlled Substances Act/s:102/p:41"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 802(41)", "@value": "usc/21/802/41"}, "@parsable-cite": "usc/21/802", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Definitions"}, "paragraph": [{"#tail": " \n", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Controlled Substances Act/s:102/p:41/sp:A"}, "#text": "in "}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "#text": "\n          ", "@id": "HADBB1B5FD2DD4EB6BD8FA4420DEDEDEF", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by striking ", "@entity-type": "act", "#text": "clause (xlix)", "@value": "Controlled Substances Act/s:102/p:41/sp:A/cl:xlix"}, "#text": "in ", "quote": {"#tail": " at the end;", "#text": "and"}}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H0F7FCBBE1D37466DA7711E2A6CFD4195", "#text": "\n            "}, {"#tail": " \n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " as ", "@entity-type": "act", "#text": "clause (xlx)", "@value": "Controlled Substances Act/s:102/p:41/sp:A/cl:xlx"}, {"#tail": "; and", "@entity-type": "act", "#text": "clause (lxxv)", "@value": "Controlled Substances Act/s:102/p:41/sp:A/cl:lxxv", "@proposed": "true"}], "#text": "by redesignating "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "H8FD186FEE86842118DF6E03DC9C15774", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the following:", "@entity-type": "act", "#text": "clause (xlix)", "@value": "Controlled Substances Act/s:102/p:41/sp:A/cl:xlix"}, "#text": "by inserting after "}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "; and"}, "#tail": "\n          ", "clause": [{"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "5\u03b1-Androstan-3,6,17-trione;"}, "enum": {"#tail": "\n                ", "#text": "(l)"}, "#text": "\n                ", "@id": "HC2321B0A79B442BFACB98905D5F3F111"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "6-bromo-androstan-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(li)"}, "#text": "\n                ", "@id": "HE99F5D227B194F8FAD7AF853D73D0A0B"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "6-bromo-androsta-1,4-diene-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lii)"}, "#text": "\n                ", "@id": "H49844A96005A43EEB07460B97C89E4FB"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-androsta-1,4-diene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(liii)"}, "#text": "\n                ", "@id": "H3DFCBEC7D4E5426BBCCDCDAE3CD46248"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-androst-4-ene-3\u03b2,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(liv)"}, "#text": "\n                ", "@id": "HF430FE51452C407881F3DCB1FC9CE48D"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-17\u03b2-hydroxy-androst-4-en-3-one;"}, "enum": {"#tail": "\n                ", "#text": "(lv)"}, "#text": "\n                ", "@id": "H027127650163401FA2F09F101546FE3A"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-17\u03b2-hydroxy-androst-4-ene-3,11-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lvi)"}, "#text": "\n                ", "@id": "HAA0E58FEE6334535986B5933D5B2CF4B"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-chloro-17\u03b1-methyl-androsta-1,4-diene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(lvii)"}, "#text": "\n                ", "@id": "HBC1406CE9A5C4FF586FEFF43BD8EDAEA"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "2\u03b1,17\u03b1-dimethyl-17\u03b2-hydroxy-5\u03b1-androstan-3-one;"}, "enum": {"#tail": "\n                ", "#text": "(lviii)"}, "#text": "\n                ", "@id": "HB1E278EECDB04734B4C817999C4650D9"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "2\u03b1,17\u03b1-dimethyl-17\u03b2-hydroxy-5\u03b2-androstan-3-one;"}, "enum": {"#tail": "\n                ", "#text": "(lix)"}, "#text": "\n                ", "@id": "HE16AE828C3434FC494F185CFDEB6DEBB"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "2\u03b1,3\u03b1-epithio-17\u03b1-methyl-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lx)"}, "#text": "\n                ", "@id": "H6AD8DC96472D487E98720E98AC5ABF60"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "[3,2-c]-furazan-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxi)"}, "#text": "\n                ", "@id": "H4E08EDE78F9E4547BC688CAB3994D1AB"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "3\u03b2-hydroxy-estra-4,9,11-trien-17-one;"}, "enum": {"#tail": "\n                ", "#text": "(lxii)"}, "#text": "\n                ", "@id": "H94A55DCAADF94E7387E9C0797F258679"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b1-methyl-androst-2-ene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(lxiii)"}, "#text": "\n                ", "@id": "H38324C03B6EF41729E14B329D0C2DF7B"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b1-methyl-androsta-1,4-diene-3,17\u03b2-diol;"}, "enum": {"#tail": "\n                ", "#text": "(lxiv)"}, "#text": "\n                ", "@id": "HE304CD9CFA3D4F09BEC18691958015C8"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "Estra-4,9,11-triene-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lxv)"}, "#text": "\n                ", "@id": "HA42764977A934AFA8F57468F4C4B9925"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "18a-Homo-3-hydroxy-estra-2,5(10)-dien-17-one;"}, "enum": {"#tail": "\n                ", "#text": "(lxvi)"}, "#text": "\n                ", "@id": "H12E67564D6AA406ABAFBDB5017743AA5"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "6\u03b1-Methyl-androst-4-ene-3,17-dione;"}, "enum": {"#tail": "\n                ", "#text": "(lxvii)"}, "#text": "\n                ", "@id": "H0B2729B2B73C4B17AF818473087F3D4F"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b1-Methyl-androstan-3-hydroxyimine-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxviii)"}, "#text": "\n                ", "@id": "H047ADE4CC74440D6A3E66C1A36D042A7"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b1-Methyl-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxix)"}, "#text": "\n                ", "@id": "H2A6C993FA28748D19F14867A9227A109"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b2-Hydroxy-androstano[2,3-d]isoxazole;"}, "enum": {"#tail": "\n                ", "#text": "(lxx)"}, "#text": "\n                ", "@id": "H5AFAF56CEE244F19B0BC2016852D3024"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "17\u03b2-Hydroxy-androstano[3,2-c]isoxazole;"}, "enum": {"#tail": "\n                ", "#text": "(lxxi)"}, "#text": "\n                ", "@id": "HB19E2DB229E24E5E9C548BD04BE33D34"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "4-Hydroxy-androst-4-ene-3,17-dione[3,2-c]pyrazole-5\u03b1-androstan-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxxii)"}, "#text": "\n                ", "@id": "H8BC30A6213384072B0D7212BA7DC7354"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": "\n              ", "#text": "[3,2-c]pyrazole-androst-4-en-17\u03b2-ol;"}, "enum": {"#tail": "\n                ", "#text": "(lxxiii)"}, "@display-inline": "no-display-inline", "#text": "\n                ", "@id": "H68186E0BFC054DC3AA0B2F2EDD68A98E", "@commented": "no"}, {"@indent": "paragraph", "#tail": "\n              ", "text": {"#tail": "\n              ", "#text": "[3,2-c]pyrazole-5\u03b1-androstan-17\u03b2-ol; and"}, "enum": {"#tail": "\n                ", "#text": "(lxxiv)"}, "#text": "\n                ", "@id": "H518ECAE3CB3F41AAB0D46A61440E0CC0"}], "@display-inline": "no-display-inline", "#text": " \n", "@id": "HBB8C608CEA7846B399706D25220329C5"}, "#text": "\n            ", "@id": "H41A6CA8E13104226842119F935265BFE"}]}, {"#tail": "\n      ", "text": {"#tail": " \n", "#text": "by adding at the end the following:"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n        ", "@id": "HFC5BB19B5C4543F6AA5450E594BAECB1", "@display-inline": "no-display-inline", "#text": " \n", "subparagraph": {"@indent": "subsection", "#tail": "\n            ", "clause": [{"#tail": " \n", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", a drug or hormonal substance (other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone) that is not listed in ", "@entity-type": "act", "#text": "clause (ii)", "@value": "Controlled Substances Act/s:102/p:41/sp:C/cl:ii", "@proposed": "true"}, {"#tail": " and is derived from, or has a chemical structure substantially similar to, 1 or more anabolic steroids listed in ", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Controlled Substances Act/s:102/p:41/sp:A"}, {"#tail": " shall be considered to be an anabolic steroid for purposes of this Act if\u2014", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Controlled Substances Act/s:102/p:41/sp:A"}], "#text": "Subject to "}, "enum": {"#tail": "\n                ", "#text": "(i)"}, "subclause": [{"@indent": "subparagraph", "#tail": " \n", "text": {"#tail": " \n", "#text": "the drug or substance has been created or manufactured with the intent of producing a drug or other substance that either\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "item": [{"@indent": "clause", "#tail": " \n", "text": {"#tail": "\n                  ", "#text": "promotes muscle growth; or"}, "enum": {"#tail": "\n                    ", "#text": "(aa)"}, "#text": "\n                    ", "@id": "HFE73AAE94E8D4DCA89E94AFA489ED337"}, {"@indent": "clause", "#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "otherwise causes a pharmacological effect similar to that of testosterone; or"}, "enum": {"#tail": "\n                    ", "#text": "(bb)"}, "#text": "\n                    ", "@id": "HD6DDE17401154303AF2FE75121F96EDC"}], "#text": "\n                  ", "@id": "HE3B99B322DB1437CA6A098980DCD41E2"}, {"@indent": "subparagraph", "#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "the drug or substance has been, or is intended to be, marketed or otherwise promoted in any manner suggesting that consuming it will promote muscle growth or any other pharmacological effect similar to that of testosterone."}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "#text": "\n                  ", "@id": "H7BA129A07FCE4E668005C2155222A481"}], "@display-inline": "yes-display-inline", "#text": "\n                ", "@id": "H04CE2141481A41909A2962144DFABD60", "@commented": "no"}, {"@indent": "paragraph", "#tail": " \n", "text": {"#tail": " \n", "#text": "A substance shall not be considered to be a drug or hormonal substance for purposes of this subparagraph if it\u2014"}, "enum": {"#tail": "\n                ", "#text": "(ii)"}, "subclause": [{"@indent": "subparagraph", "#tail": " \n", "text": {"#tail": " \n", "#text": "is\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(I)"}, "item": [{"@indent": "clause", "#tail": " \n", "text": {"#tail": "\n                  ", "#text": "an herb or other botanical;"}, "enum": {"#tail": "\n                    ", "#text": "(aa)"}, "#text": "\n                    ", "@id": "HED37DD873B9C4616886373E07CEFB321"}, {"@indent": "clause", "#tail": " \n", "text": {"#tail": "\n                  ", "#text": "a concentrate, metabolite, or extract of, or a constituent isolated directly from, an herb or other botanical; or"}, "enum": {"#tail": "\n                    ", "#text": "(bb)"}, "#text": "\n                    ", "@id": "H02B0C4C7E52849EDA04A73F00CFE4457"}, {"@indent": "clause", "#tail": "\n                ", "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "item (aa)", "@value": "Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:aa", "@proposed": "true"}, {"#tail": ";", "@entity-type": "act", "#text": "(bb)", "@value": "Controlled Substances Act/s:102/p:41/sp:C/cl:ii/scl:I/i:bb", "@proposed": "true"}], "#text": "a combination of 2 or more substances described in "}, "enum": {"#tail": "\n                    ", "#text": "(cc)"}, "#text": "\n                    ", "@id": "HFEE97B1D825A4B8CBF01CD8BC69D446A"}], "#text": "\n                  ", "@id": "H8A528D30F3AF4044B0765668E8937047"}, {"@indent": "subparagraph", "#tail": " \n", "text": {"#tail": "\n                ", "#text": "is a dietary ingredient for purposes of the ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "; and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}, "@entity-type": "law-citation", "#text": "\n                      ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "uscode", "#text": "21 U.S.C. 301 et seq.", "@value": "usc/21/301/etseq"}, "@parsable-cite": "usc/21/301", "#text": "\n                      ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n                  ", "#text": "(II)"}, "#text": "\n                  ", "@id": "H08B57F7299BC436EA78F7EF043FFFE5E"}, {"@indent": "subparagraph", "#tail": "\n              ", "text": {"#tail": "\n                ", "#text": "is not anabolic or androgenic.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(III)"}, "#text": "\n                  ", "@id": "H41D7041D55FA4C65821E75B9294C602C"}], "#text": "\n                ", "@id": "HFC38C3C111734C33BE05C401F455C05C"}, {"@indent": "paragraph", "#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", any person claiming the benefit of an exemption or exception under ", "@entity-type": "act", "#text": "section 515(a)", "@value": "Controlled Substances Act/s:515/p:a"}, {"#tail": " shall bear the burden of going forward with the evidence with respect to such exemption or exception.", "@entity-type": "act", "#text": "clause (ii)", "@value": "Controlled Substances Act/s:102/p:41/sp:C/cl:ii", "@proposed": "true"}], "#text": "In accordance with "}, "enum": {"#tail": "\n                ", "#text": "(iii)"}, "#text": "\n                ", "@id": "HCF313A1F84A64B659AD9C75CC00A2211"}], "enum": {"#tail": " \n", "#text": "(C)"}, "#text": "\n              ", "@id": "HF81DD0EB56914B03BB4E06FE1E646F8D"}}, "#text": "\n          ", "@id": "H07693AB59818443CB3734CF754FB66E5"}], "#text": "\n        ", "@id": "H7B5A17B28267408BAA565BB19728976E"}, {"#tail": "\n    ", "text": {"#tail": " \n", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 201 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:201"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 811", "@value": "usc/21/811"}, "@parsable-cite": "usc/21/811", "#text": "\n            ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Classification authority"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "subsection": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(i)"}, "header": {"#tail": " \n", "#text": "Temporary and permanent scheduling of recently emerged anabolic steroids"}, "paragraph": [{"#tail": " \n", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may issue a temporary order adding a drug or other substance to the definition of anabolic steroids if the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " finds that\u2014", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "#text": "\n              ", "@id": "H641D3062668146918D2FFD1F9128B73D", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " but is not listed in that section or by regulation of the ", "@entity-type": "act", "#text": "section 102(41)", "@value": "Controlled Substances Act/s:102/ss:41"}, {"#tail": " as being an anabolic steroid; and", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}], "#text": "the drug or other substance satisfies the criteria for being considered an anabolic steroid under "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H2ACB05C0D27A4C5892538E87DD0C6623", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "#text": "adding such drug or other substance to the definition of anabolic steroids will assist in preventing abuse or misuse of the drug or other substance.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H05D5DC2CD40344A6B1031E42FBB096A6", "#text": "\n                "}]}, {"#tail": " \n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall not take effect until 30 days after the date of the publication by the ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:102/ss:i/p:1", "@proposed": "true"}, {"#tail": " of a notice in the Federal Register of the intention to issue such order and the grounds upon which such order is to be issued. The order shall expire not later than 24 months after the date it becomes effective, except that the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " may, during the pendency of proceedings under ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": ", extend the temporary scheduling order for up to 6 months.", "@entity-type": "act", "#text": "paragraph (6)", "@value": "Controlled Substances Act/s:102/ss:i/p:6", "@proposed": "true"}], "#text": "An order issued under "}, "enum": {"#tail": "\n              ", "#text": "(2)"}, "@id": "H29B4A04BECBE4B3095325E5C00C1DD93", "#text": "\n              "}, {"#tail": " \n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall transmit notice of an order proposed to be issued under ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " to the ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:102/ss:i/p:1", "@proposed": "true"}, {"#tail": ". In issuing an order under ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, {"#tail": ", the ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:102/ss:i/p:1", "@proposed": "true"}, {"#tail": " shall take into consideration any comments submitted by the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " in response to a notice transmitted pursuant to this paragraph.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "@id": "H3615C89A23C348C78AD810ACC5868FFC", "#text": "\n              "}, {"#tail": " \n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall be vacated upon the issuance of a permanent scheduling order under ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:102/ss:i/p:1", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (6)", "@value": "Controlled Substances Act/s:102/ss:i/p:6", "@proposed": "true"}], "#text": "A temporary scheduling order issued under "}, "enum": {"#tail": "\n              ", "#text": "(4)"}, "@id": "HA0024484F5894475B5314350226AFBBF", "#text": "\n              "}, {"#tail": " \n", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " is not subject to judicial review.", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:102/ss:i/p:1", "@proposed": "true"}, "#text": "An order issued under "}, "enum": {"#tail": "\n              ", "#text": "(5)"}, "@id": "H39721FC8418748029C7484ADD6F05548", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n            ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, by rule, issue a permanent order adding a drug or other substance to the definition of anabolic steroids if such drug or other substance satisfies the criteria for being considered an anabolic steroid under ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": ". Such rulemaking may be commenced simultaneously with the issuance of the temporary order issued under ", "@entity-type": "act", "#text": "section 102(41)", "@value": "Controlled Substances Act/s:102/ss:41"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Controlled Substances Act/s:102/ss:i/p:1", "@proposed": "true"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(6)"}, "@id": "HE22D7AE7B9BF4884A7AF95AFACB2E3F7", "#text": "\n              "}], "#text": "\n            ", "@id": "H9BB30F1DA98C43E0AC1244142122AD06"}, "@display-inline": "no-display-inline", "#text": " \n", "@id": "H7A9F6C19323F4492AB7F0EDA494ADDE5"}, "#text": "\n        ", "@id": "HF18AED7CE5EB473FAF90C645D4FB2F8B"}], "#text": "\n      ", "@id": "H13BF72572A9941B4A215ACA60DE702B3"}, {"#tail": " \n", "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": " \n", "#text": "Labeling requirements"}, "subsection": [{"#tail": " \n", "text": {"#tail": " \n", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 305 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:305"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 825", "@value": "usc/21/825"}, "@parsable-cite": "usc/21/825", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n      ", "subsection": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(e)"}, "header": {"#tail": " \n", "#text": "False Labeling of Anabolic Steroids"}, "paragraph": [{"#tail": " \n", "text": {"#tail": "\n            ", "#text": "It shall be unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, an anabolic steroid or product containing an anabolic steroid, unless the steroid or product bears a label clearly identifying an anabolic steroid or product containing an anabolic steroid by the nomenclature used by the International Union of Pure and Applied Chemistry (IUPAC).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "@id": "H73174643E5464EFFA8C234DE7B26D918", "#text": "\n              "}, {"#tail": "\n          ", "@id": "H93B24532904242D9A3064B347B210B0B", "enum": {"#tail": " \n", "#text": "(2)"}, "#text": "\n              ", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " is exempt from the International Union of Pure and Applied Chemistry nomenclature requirement of this subsection if such product is labeled in the manner required under the ", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "Controlled Substances Act/s:305/ss:e/p:2/sp:B", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}], "#text": "A product described in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@display-inline": "yes-display-inline", "#text": "\n                ", "@id": "HBED11304AEA04E45B62C2E12BCE2A6B4", "@commented": "no"}, {"@indent": "up1", "#tail": "\n            ", "text": {"#tail": " \n", "#text": "A product is described in this subparagraph if the product\u2014"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "clause": [{"#tail": " \n", "text": {"#tail": "\n                ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 505(b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:b"}, {"#tail": "; or", "@entity-type": "act", "#text": "(j) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:j"}], "#text": "is the subject of an approved application as described in "}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "#text": "\n                  ", "@id": "H55F6C561DF1F413788C71A580303BE27", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " of such Act relating to new drugs because\u2014", "@entity-type": "act", "#text": "section 505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, "#text": "is exempt from the provisions of "}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "subclause": [{"#tail": " \n", "text": {"#tail": "\n                  ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "act", "#text": "section 505(i) of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:i"}, "#text": "it is intended solely for investigational use as described in "}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "#text": "\n                    ", "@id": "H4BA07926DA10447C8B9FA93309E6BEDD", "@commented": "no"}, {"#tail": "\n                ", "text": {"#tail": "\n                  ", "#text": "such product is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application."}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "#text": "\n                    ", "@id": "HB000C994FFA14FDD81C27DC7F184C1B3", "@commented": "no"}], "#text": "\n                  ", "@id": "H744840E54DD5464EB62277461697555B", "@commented": "no"}], "#text": "\n                ", "@id": "H54D459F42B254216AF013DD160E1735E", "@commented": "no"}], "@commented": "no"}], "#text": "\n            ", "@id": "H93CE492FACE14A38B8339104EB37B4AD"}, "@display-inline": "no-display-inline", "#text": " \n", "@id": "HECF14BA2DE7A4935BE83FFB891E2BFBD"}, "#text": "\n        ", "@id": "H9BF569951C5F409AB06D485D2B34CB6D"}, {"#tail": " \n", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by inserting ", "@entity-type": "act", "#text": "subsection (a)(1)", "@value": "Controlled Substances Act/s:1010/ss:a/p:1"}, "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended, in ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 1010 of the Controlled Substances Import and Export Act", "@value": "Controlled Substances Act/s:1010"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 960", "@value": "usc/21/960"}, "@parsable-cite": "usc/21/960", "#text": "\n            ", "@legal-doc": "usc"}}, "quote": [{"#tail": " before ", "#text": "\n            305,"}, {"#tail": ".", "#text": "\n            1002\n          "}]}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Clarification to Import and Export statute"}, "#text": "\n        ", "@id": "HCAE47999B3024DB48C6F01E20878801C"}, {"#tail": "\n    ", "text": {"#tail": " \n", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 402 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:402"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 842", "@value": "usc/21/842"}, "@parsable-cite": "usc/21/842", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Civil penalties"}, "paragraph": [{"#tail": " \n", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Controlled Substances Act/s:402/ss:a"}, "#text": "in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "#text": "\n          ", "@id": "H3703E5FCF5A64940A93CDB1752EFE085", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by striking ", "@entity-type": "act", "#text": "paragraph (14)", "@value": "Controlled Substances Act/s:402/ss:a/p:14"}, "#text": "in ", "quote": {"#tail": " at the end;", "#text": "or"}}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H5DD46699E82E476A9B487E068496C6B9", "#text": "\n            "}, {"#tail": " \n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by striking the period at the end and inserting ", "@entity-type": "act", "#text": "paragraph (15)", "@value": "Controlled Substances Act/s:402/ss:a/p:15"}, "#text": "in ", "quote": {"#tail": "; and ", "#text": "; or"}}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "HAF4AD37388EA4E2396EB54525B3240C3", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the following:", "@entity-type": "act", "#text": "paragraph (15)", "@value": "Controlled Substances Act/s:402/ss:a/p:15"}, "#text": "by inserting, after "}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "; and"}, "#tail": "\n          ", "paragraph": {"#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (e) of section 305 of the Controlled Substances Act", "@value": "Controlled Substances Act/s:305/ss:e", "@proposed": "true"}, "#text": "to violate ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(16)"}, "@id": "H3CB5C3EE65A94244B4E7196B12681B87", "#text": "\n                "}, "@display-inline": "no-display-inline", "#text": " \n", "@id": "HED92EE21056546148BE668827F0B6E29"}, "#text": "\n            ", "@id": "HA49B307F8E3F4C1DB5E5FD893C98EE19"}]}, {"#tail": "\n      ", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "act", "#text": "subsection (c)(1)", "@value": "Controlled Substances Act/s:402/ss:c/p:1"}, "#text": "in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "#text": "\n          ", "@id": "HE5B26DBABAF14F79883DCE72BC8ACA40", "subparagraph": [{"#tail": " \n", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", after ", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Controlled Substances Act/s:402/ss:c/p:1/sp:A"}, "quote": [{"#tail": " the following: ", "#text": "\n                subparagraph (B)\n              "}, {"#tail": "; and", "#text": ", (C), or (D)\n              "}], "#text": "by inserting, in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "HA61D508DC37C4AF68034A99565040FC1", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": " \n", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the following: ", "@entity-type": "act", "#text": "subparagraph (B)", "@value": "Controlled Substances Act/s:402/ss:c/p:1/sp:B"}, "#text": "by inserting after "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": "."}, "#tail": "\n          ", "@id": "H3C85762BD7E640EB956AF42B725FCA22", "@display-inline": "no-display-inline", "#text": " \n", "subparagraph": [{"@indent": "subsection", "#tail": " \n", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " of this section by an importer, exporter, manufacturer, or distributor (other than as provided in ", "@entity-type": "act", "#text": "paragraph (16) of subsection (a)", "@value": "Controlled Substances Act/s:402/ss:a/p:16", "@proposed": "true"}, {"#tail": "), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of ", "@entity-type": "act", "#text": "subparagraph (D)", "@value": "Controlled Substances Act/s:402/ss:c/p:1/sp:D", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "paragraph (16) of subsection (a)", "@value": "Controlled Substances Act/s:402/ss:a/p:16", "@proposed": "true"}], "#text": "In the case of a violation of ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "#text": "\n                ", "@id": "HCAB14273B86248C1B915CBFEBEAFA087"}, {"@indent": "subsection", "#tail": "\n              ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " of this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term ", "@entity-type": "act", "#text": "paragraph (16) of subsection (a)", "@value": "Controlled Substances Act/s:402/ss:a/p:16", "@proposed": "true"}, {"#tail": " shall be considered a separate violation. ", "@entity-type": "act", "#text": "paragraph (16) of subsection (a)", "@value": "Controlled Substances Act/s:402/ss:a/p:16", "@proposed": "true"}], "quote": {"#tail": " refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of ", "#text": "at the retail level"}, "#text": "In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "#text": "\n                ", "@id": "HD7AD338646174761835B839085BE1E0A"}]}, "#text": "\n            ", "@id": "H1030A8E7022C4C89A305D76C3D012A8A"}]}], "#text": "\n        ", "@id": "HAED1492D84334644A579854219B97762"}], "#text": "\n      ", "@id": "H8CFC62AC998B4B7E9DD188DA8C017C26"}, {"#tail": " \n", "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": " \n", "#text": "Identification and publication of list of products containing anabolic steroids"}, "subsection": [{"#tail": " \n", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may, in his discretion, collect data and analyze products to determine whether they contain anabolic steroids and are properly labeled in accordance with this section. The ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " may publish in the Federal Register or on the website of the ", "@entity-type": "federal-body", "#text": "Attorney General", "@entity-id": "1500"}, {"#tail": " a list of products that he has determined, based on substantial evidence, contain an anabolic steroid and are not labeled in accordance with this section.", "@entity-type": "federal-body", "#text": "Drug Enforcement Administration", "@entity-id": "1524"}], "#text": "The ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "@id": "HF18612CE54CA4B1BB58AD01A7C2BF248", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n      ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall not constitute evidence that the product does not contain an anabolic steroid.", "@entity-type": "act", "#text": "subsection (a)", "@value": "Designer Anabolic Steroid Control Act of 2014/s:4/ss:a", "@proposed": "true"}, "#text": "The absence of a product from the list referred to in ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "@id": "HB9B321A069B34BE685CD2FC7A3109881", "#text": "\n        "}], "#text": "\n      ", "@id": "H28244B815352468E8C821EBFEF6156DE"}], "@display-enacting-clause": "no-display-enacting-clause", "@reported-display-style": "boldface-roman", "#text": " \n", "@id": "HEFB1AAE712C94DA58AA98ACF00792C01"}], "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-09-15"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 4771 RH: Designer Anabolic Steroid Control Act of 2014"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}